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Abstract
Background: A new clinical syndrome has been recognized following the COVID-19 vaccine, termed thrombosis with throm-
bocytopenia syndrome (TTS). The following systematic review focuses on extrapolating thrombotic risk factors, clinical manifes-
tations, and outcomes of patients diagnosed with TTS following the COVID-19 vaccine.
Methods: We utilized the World Health Organization’s criteria for a confirmed and probable case of TTS following COVID-19
vaccination and conducted a systematic review and posthoc analysis using the PRISMA 2020 statement. Data analysis was con-
ducted using SPSS V25 for factors associated with mortality, including age, gender, anti-PF4/heparin antibodies, platelet nadir, D-
dimer peak, time to event diagnosis, arterial or venous thrombi.
Results:Of the 175 studies identified, a total of 25 studies with 69 patients were included in this systematic review and post hoc
analysis. Platelet nadir (P< .001), arterial or venous thrombi (χ2= 41.911, P= .05), and chronic medical conditions (χ2= 25.507, P
= .041) were statistically associated with death. The ROC curve analysis yielded D-dimer (AUC= .646) and platelet nadir (AUC
= .604) as excellent models for death prediction.
Conclusion: Adenoviral COVID-19 vaccines have been shown to trigger TTS, however, reports of patients having received
mRNA COVID-19 vaccines are also present. Healthcare providers are recommended to maintain a high degree of suspicion
among individuals who have received the COVID-19 vaccine within the last 4 weeks.
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Introduction
In February of 2021, a new clinical syndrome was docu-
mented among patients who received the ChAdOx1
nCoV-19 AstraZeneca (AZ) vaccine and similar trends
were noted for the Ad26.COV2. S Johnson & Johnson (JJ)
vaccines in April 2021.1,2 Now termed “Thrombosis with
thrombocytopenia syndrome” (TTS), known also as
“vaccine-induced immune thrombotic thrombocytopenia”
(VITT) or “vaccine-induced prothrombotic immune throm-
bocytopenia” (VIPIT), TTS is a clinical syndrome that has
been recognized following the administration of two adeno-
virus vector-based vaccines, including the AD26.COV2. S JJ
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vaccine and ChAdOx1 nCoV-19 AZ vaccine.3 Both the vac-
cines encode for the SARS-CoV-2 spike protein immunogen
via recombinant adenoviral vectors, chimpanzee for AZ and
human for JJ.4 TTS is similar to heparin-induced thrombocy-
topenia (HIT), despite the absence of heparin exposure, given
firstly, its clinical presentation with venous or arterial throm-
bosis at odd sites including cerebral venous sinus thrombosis
(CVST) and splanchnic vein thrombosis, secondly, the
varying degrees of thrombocytopenia, and thirdly, positive
platelet factor 4 (PF-4)-dependent enzyme-linked immuno-
sorbent assay (ELISA) independent of heparin.5 The under-
lying pathophysiology is associated with IgG antibodies
that recognize PF4 and activate platelets through their Fcγ
receptors.6 This is similar to the classic HIT associated
with platelet-activating anti-PF4/heparin antibodies.
Estimated clinical manifestations of symptoms present 5 to
30 days following the vaccination.7,8 Symptoms are often
severe and persistent including severe headache, visual
changes, altered mental status, nausea, vomiting, abdominal
pain, shortness of breath, bleeding or petechial, and leg pain
or swelling. So far, CVST has been reported among two adeno-
viral vector-based (Jenssen and AstraZeneca) vaccine recipients
who are among predominantly middle-aged women. However,
these demographics may be skewed and if true, would be con-
sistent with the risk factors associated with HIT.9 The rare clin-
ical entity is similar to autoimmune HIT presentations,
clinically identified through PF4 antibodies and mild-to-severe
thrombocytopenia.10 However, the relationship between PF4
antibodies and the clinical manifestations of TTP following
vaccine administration is yet to be fully determined. While
there had been a temporary pause in the administration of JJ
and AZ, the rollout has been resumed with a focus on closely
evaluating the risks and benefits for each COVID-19 vaccine
including the close monitoring of the newly defined TTS.11 It
is unclear whether those who develop TTS have a prior
history of thrombosis or associated risk factors. There is also
no mechanistic association of thrombotic events centered on
cerebral vessels and splanchnic circulation with TTS.12
The following systematic review and posthoc analysis
provide insight into the pre-existing risk factors for thrombosis
or immunity among patients who developed TTS for relevant
therapeutic implications.
Methodology
Search Strategy and Study Selection
Using the Preferred Reporting Items for Systematic Reviews
and Meta-Analysis (PRISMA) 2020 statement, we conducted
a systematic literature search from December 2019 through
July 202113,14 The following keywords were used, by using
the Boolean logic (and/or): thrombosis, thrombocytopenia,
blood clot, DVT, embolism, VTE, clotting, covid-19, coronavi-
rus or 2019-ncov, sars-cov-2 or cov-19, vaccines, vaccinations,
immunizations. An a-priori approach was used to include the
clinical studies and ensure that the outcome measures were
listed systematically and continuously for the included
studies.15 The PRISMA flowchart is illustrated in Figure 1.
We included studies where patients either had confirmed or
probable TTS diagnosis based on the World Health
Organization’s (WHO) criteria. For this analysis, we only
included case series and case studies, whereas cohorts, system-
atic reviews, meta-analysis, letters, and editorials were
excluded. Three databases were searched including PubMed,
CINAHL Plus, and Cochrane, with an additional search of
registers (NEJM, JAMA, BMJ). To ensure that all relevant
studies were included, we screened the reference lists of
included studies (umbrella review).
Eligibility Criteria
The WHO criteria for a confirmed and probable case of TTS
following COVID-19 vaccination were used as listed below.
These case definitions imply the absence of a better alternative
explanation for the condition and are adapted from the WHO
Interim Guidance for TTS.16
Confirmed case
• Individuals who present with thrombosis (imaging, surgi-
cal or pathological) in unusual locations (cerebral,
splanchnic or multi-organ) within four weeks following
vaccination with severe thrombocytopenia (< 50× 109/
L), confirmatory peripheral smear showing reduced plate-
let, no evidence of platelet clumping, increased D-dimer
and positive anti-PF4 antibodies;Figure 1. PRISMA flowchart.
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• Positive laboratory criteria other than severe thrombocyto-
penia in patients with thrombosis in usual or unusual
locations;
• Thrombosis in unusual locations with severe thrombocy-
topenia without positive laboratory markers (eg,
anti-PF4 antibodies).
Probable case
• Individuals who present with thrombosis (imaging, surgi-
cal or pathological) in usual locations (pulmonary, limb
veins, coronary arteries or cerebral arteries) within four
weeks following vaccination with severe thrombocytope-
nia (< 50× 109/L);
• Thrombosis in unusual location with mild thrombocytope-
nia (> 50× 109/L—< 150× 109/L or > 50% decrease from
baseline) and D-dimer > 4 mg/L.
Any study that did not meet the criteria listed above was
removed.
Data Extraction and Synthesis
The following data were extracted from the included studies:
demographic data (country, age, gender), the vaccine used
and dosage, chronic medical conditions, thrombosis risk
factors, presenting complaint, anti-PF4/heparin antibodies,
platelet nadir, D-dimer peak, arterial or venous thrombi, time
to event diagnosis and mortality. All data was inputted in a
shared spreadsheet, which was extracted independently by the
three authors for analysis and cumulative result interpretation
(M.U.H., M.I., Z.S.). All discrepancies were resolved by the
fourth and fifth authors (A.S., Z.S.) and a consensus was
reached. Refer to Supplementary Table 1.
Data Analysis
The fourth and fifth authors (A.S. and Z.S.) extracted all
nominal and ordinal data for analysis using SPSS V25. A
bivariate analysis was conducted to assess the associations of
mortality to age, gender, anti-PF4/heparin antibodies, platelet
nadir (109/L), D-dimer peak (mg/L), time to event diagnosis,
arterial or venous thrombi, and treatment. The factor was con-
sidered statistically significant if the P-value was .05 or less.
Furthermore, a chi-square test of proportions was carried out
to assess associations of 1) arterial or venous thrombi, 2) throm-
bosis risk factors, and 3) chronic medical conditions to death
among the included patients. The post hoc analysis comprised
of quantitative analytical measures for associations to mortality,
where a ROC analysis was conducted with a value of .5 indicat-
ing a generally good model.
Role of Funding
No funding was obtained for this study.
Results
As illustrated in Figure 1, a total of 175 studies were identified,
of which 148 were screened and 59 were sought for retrieval. In
total, 29 studies comprising 75 patients were assessed for eligi-
bility, where 25 studies with 69 patients were included in this
systematic review and post hoc analysis. Six patients were
excluded from this study as they did not meet the WHO TTS
criteria.
Of 58 patients, 3 (5.17%) were from Canada, 1 (1.72%) from
Denmark, 1 (1.72%) from France, 18 (31.03%) from Germany,
3 (5.17%) from Italy, 1 (1.72%) from Malaysia, 7 (12.07%)
from Norway, 1 (1.72%) from Oman, 4 (6.9%) from Saudi
Arabia, 4 (6.9%) from the United Kingdom, and 15 (25.86%)
from the United States (P= .165) (Figure 2).
The results of the statistical analysis (ie, bivariate and
chi-square proportion testing) are enlisted in Table 1 along
with the summary details. The median age of all participants
was 54, ranging from 18 to 72 (P= .16). There were 51
females (73.9%) in the total sample, with 80% who remained
alive and 62.5% who died (P= .059). The most commonly
administered vaccine (N= 51, 73.9%) was a single dose of
AstraZeneca (ChAdOx1 nCoV-19), which was administered
to 20 (83.3%) individuals who died (P= .136). Anti-PF4/
heparin antibodies were present in 53 (76.8%) patients, and
they were more prevalent (87.5%) in the individuals who died
(P= .416). The median value of platelet nadir (109/L) among
the entire sample was 326, ranging from 8 to 334 (P< .001).
The median D-dimer peak (mg/L) value among the population
was 140.9, ranging from 1.1 to 142 (P= .419). The mean±
standard deviation duration for time to event diagnosis in
days was 10.4± 8.14 in the alive group and 7.67± 5.95 in the
dead group (P= .109). The chi-square test determined that arte-
rial or venous thrombi (χ2= 41.911, P= .05) and chronic
medical conditions (χ2= 25.507, P= .041) led to a statistically
higher likelihood of death.
The results of the ROC curve for vaccine dosage, gender,
and age using death as the reference line. Similar associations
were found for the area under the curve (AUC) for the
vaccine type (AUC= .556), gender (AUC= .593), and age
(AUC= .582). The AUC for the country was computed to be
.731, suggesting that some countries of origin were strongly
associated with mortality. While the ROC curve for platelet
nadir, D-dimer peak was not presented in the figure, the findings
were significant with the strongest associations of death to
D-dimer peak (AUC= .646), suggesting that it was an excellent
model for death prediction. This was closely followed by plate-
let nadir (AUC= .604), which is considered to be a generally
good model. (Figure 3)
Discussion
To the best of our knowledge, this is the first quantitative ana-
lytical study to explore confirmed or probable TTS of cases
reported in the literature. The most commonly implicated
vaccine and the dose was a single dose of AstraZeneca
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(ChAdOx1 nCoV-19) among 73.9% (n= 51) of the included
patients. Other vaccines and doses were one dose of Janssen
(Ad26.COV2.S) (n= 12, 17.4%), one dose of Pfizer/
BioNTech (BNT162b2) (n= 2, 2.9%), two doses of Pfizer/
BioNTech (BNT162b2) (n= 2, 2.9%), and two doses of
Moderna (mRNA-1273) (n= 1, 1.4%) vaccines. Since March
2021, two vaccines that have been associated with TTS are
the ChAdOx1 nCoV-19 (Oxford-AstraZeneca, also known as
Vaxzevria) and AD26.COV2.S (Johnson & Johnson) vaccines.
Plausible mechanistic links have been evaluated between both
these adenovirus-vectored vaccines and TTS.17 Adenovirus-
based COVID-19 vaccines have demonstrated thrombogenic
potential with various mechanistic models being considered.18
TTS has been identified as a result of breached immune tolerance
and autoantibodies to PF-4. The underlying pathophysiology of
TTS is similar to that of spontaneous HIT syndrome associated
with heparin-independent platelet-activating anti-PF4 antibod-
ies.19 However, in the case of TTS, it may be suspected that
the polyanions substituting for heparin may include immuno-
genic complexes present in the adenoviral-vectored COVID-19
vaccine. The contributory mechanisms are unclear but the
vaccine components such as viral proteins of free DNA may
bind to PF4 resulting in a neoantigen.20 The post-vaccination
antibodies are hypothesized, therefore, to be formed against
PF4 as a consequence of the immune stimulation.
However, our findings suggest that mRNA vaccine recipi-
ents receiving first or second doses of BNT162b2 (Pfizer/
BioNTech) and second doses of mRNA-1273 (Moderna) vac-
cines were also noted to develop TTS, albeit less commonly
reported thus far. In both types of vaccinations (eg mRNA
and adenovirus vector vaccines), our analysis suggested
similar presentations of increased incidence of cerebral
venous sinus thrombosis (CVST), concurrent thromboses in
select patients, thrombocytopenia, elevated d-dimer, anti-
platelet 4 antibodies (anti-PF4), and associated mortality.
We identified 69 patients with a median age of 54 [18 to 72]
years and 73.9% females (n= 51). Our findings gain support
from the literature regarding the AstraZeneca vaccine of a
higher prevalence in women and patients aged < 60 years
within 2 weeks of first vaccine dose.21 According to the
EMA’s Pharmacovigilance Risk Assessment Committee
(PRAC), as of June 27, 2021, 479 cases of suspected TTS
were identified from EU/EEA countries of which 100 were
fatal, with an incidence of 9.3 per million doses of
AstraZeneca vaccine administered.22 TTS cases in the US as
reported by the Center for Disease Control and Prevention
(CDC) followed trends already observed in European cases
with women younger than 60 years and no diagnosed thrombo-
philia,17,23 supporting our analytical findings of no further risk
with underlying thrombotic risk factors (eg thrombophilia, con-
traceptive pill use).
The European and US cases both identified positive
heparin-PF4 antibody ELISA tests without prior use of
heparin, suggesting autoimmune HIT as a plausible mechanism,
similar to our findings.16 In our exploratory analysis, the overall
number of patients who tested positive for heparin-PF4 antibod-
ies was higher among patients who had died (87.5% vs 71.1%).
In the initial European CVST reports, 88% of the patients had
positive HIT antibody tests which were not observed in the
US cases (11%).1,24,25 The lack of standardization by different
laboratories may have resulted in the noted discrepancies.26
However, the insight of current TTS cases following
COVID-19 vaccination is still developing, requiring further
investigations into the development of TTS following both
adenovirus-vector and mRNA vaccines.
Other factors found in our analysis that were associated
with the highest mortality following TTS diagnosis include
chronic medical conditions (eg, comorbidities, obesity, and
hypothyroidism). Independent case series were reported ini-
tially in the New England Journal of Medicine among
patients who received the ChAdOx1 nCoV-19 AstraZeneca
vaccine, and patients were healthy at the time of vaccina-
tion.8,25,27 Underlying comorbidities, though not reported
as contributors to the severity of TTS so far, are expected
Figure 2. The country of origin for 58 patients. UK=United Kingdom, US=United States.
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to worsen prognosis as demonstrated in our analysis.
Early-onset presentation (7 vs 10 days at presentation) was
also associated with higher mortality risk which suggests
that the first 2 weeks following vaccination is critical and
the most common symptoms were persistent headache,
body aches, fever, and lateralizing signs.
Table 1. Summary of results and associations to mortality trends.
Total sample (N= 69) Alive (N= 45) Dead (N=24) p-value
Age 54 [18 to 72]; N= 47 54 [18 to 72] (N= 32) 45 [24 to 69]; N= 15 P= .16
Female 51 (73.9%) 36 (80%) 15 (62.5%) P= .059
Vaccine type P= .136
1 dose of AstraZeneca
(ChAdOx1 nCoV-19) vaccine
51 (73.9%) 31 (68.9%) 20 (83.3%)
1 dose of Pfizer/BioNTech
(BNT162b2) vaccine
2 (2.9%) 2 (4.4%) -
2 doses of Pfizer/BioNTech
(BNT162b2) vaccine
2 (2.9%) 2 (4.4%) -
1 dose of Janssen (Ad26.COV2.S)
vaccine
12 (17.4%) 9 (20%) 3 (12.5%)
2 doses of Moderna
(mRNA-1273) vaccine
1 (1.4%) 2 (4.4%) 1 (4.2%)
2 doses, name not specified 1 (1.4%) 1 (2.2%) -
Anti-PF4/heparin antibodies
(+ )
53 (76.8%) 32 (71.1%) 21 (87.5%) P= .416
Platelet nadir (109 /L) 326 (8-334); N= 65 326 (8-334); N= 43 86 (8-94); N= 22 P<
.001*
D-dimer peak (mg/L) 140.9 (1.1-142); N= 28 115.7 (1.8-117.5); N= 23 140.9 (1.1-142); N= 5 P= .419
Time to event diagnosis 9.45± 7.52 10.4± 8.14 7.67± 5.95 P= .109
Arterial or venous thrombi CVST= 47 (68.1%) CVST= 27 (60%) CVST= 20 (83.3%) P= .05*
PE= 20 (29%) PE= 15 (33.3%) PE= 5 (20.8%)
Thrombosis= 18 (26.1%) Thrombosis= 14 (31.1%) Thrombosis= 4 (16.7%)
DVT= 12 (17.4%) DVT= 11 (24.4%) DVT= 1 (4.2%)
Thrombosis risk factors Combined OCP= 5 (7.3%) Combined OCP use= 3
(6.6%)
Combined OCP= 2 (8.3%) P= .137
Factor mutation= 5 (7.3%) Factor II mutation= 1
(2.2%)
Contraceptive vaginal ring= 2
(8.3%)
Smoking= 5 (7.3%) Factor V Leiden mutation=
1 (2.2%)
HRT use= 1 (4.2%)
Smoking= 2 (8.3%)
Smoking= 3 (6.6%) Factor V Leiden mutation= 2 (8.3%)
Factor XIII deficiency= 1 (4.2%)
Heterozygous MTHFR C677T,
folate deficiency= 1 (4.2%)
Chronic medical conditions Obesity= 11 (15.9%) Obesity= 9 (20%) Obesity= 2 (8.3%) P=
.041*HTN= 4 (5.8%) HTN= 4 (8.8%) HTN= 3 (12.5%)
Type 2 DM= 3 (4.4%) Type 2 DM= 4 (8.8%) Type 2 DM= 1 (4.2%)
Hypothyroidism= 3 (4.4%) Hypothyroidism= 2 (4.4%) Hypothyroidism= 1 (4.2%)
CAD= 2 (2.9%) CAD= 1 (2.2%) CAD= 1 (4.2%)
Treatment Apixaban= 3 (4.4%) Apixaban= 3 (6.6%) Dabigatran= 1 (4.2%) P= .082
Argatroban= 6 (8.7%) Argatroban= 6 (13.3%) Heparin= 7 (29.2%)
Danaparoid= 3 (4.4%) Danaparoid= 3 (6.6%) IVIG= 7 (29.2%)





Platelet transfusion= 7 (29.2%)
Heparin= 18 (26.1%) Heparin= 11 (24.4%) Steroids= 4 (16.6%)
IVIG= 25 (36.2%) IVIG= 18 (40%) UFH= 2 (8.3%)






Steroids= 7 (10.1%) UFH= 3 (6.6%)
UFH= 5 (7.3%)
*P values are considered statistically significant if < 0.05.
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We explored cases by patient profiles and specific vaccines
used; the risk denominators that cause higher mortality rates
were patient-specific (eg lower age, female gender, early pre-
sentation, chronic medical conditions), and clinical (eg severe
thrombocytopenia, markedly elevated d-dimer levels). The
results described in this investigation show a cluster of symp-
toms within 1 to 2 weeks of vaccination, primarily after first
dose but cases have also been identified after second dose (spe-
cifically for the Moderna mRNA vaccine). The Global
Advisory Committee on Vaccine Safety (GACS) has suggested
a possible link between platform-specific mechanisms associ-
ated with adenovirus vector vaccines.28 However, our results
have important implications following the identification of
TTS in 4 cases who received mRNA vaccines (Pfizer/
BioNTech after both first and second dose and Moderna after
second dose). Our findings also gain support from expert guide-
lines to consider thrombi and elevated d-dimer levels with
accompanied thrombocytopenia as suggestive of TTS, regard-
less of type or dose of vaccine administered.
The results have important implications for global vaccina-
tion efforts with speed and safety. Robust pharmacovigilance
will minimize uncertainty in the medical community and the
public. In patients who have developed ITP or thrombocytope-
nia due to other causes, a PF-4 ELISA may be utilized if there is
a significant decrease in platelet count even in absence of
thrombosis within the time frame of 4 to 30 days’ post-vaccine
as a screening measure. Importantly, there is a lack of standard-
ization of functional platelet HIT antibody assays which may be
necessary to consider when assessing TTS.29 An adjustment of
the testing methods for TTS will improve the detection and pos-
sible under-reporting of the clinical syndrome.
Overall, our findings demonstrate that the risk of TTS is sig-
nificantly higher among young women aged 18 to 59 years and
patients with comorbidities. These individuals as well as others
who develop a suspicion of TTS may benefit from timely clin-
ical detection and management.30 However, it is important to
note that these events are very rare with the highest incidence
trends for AstraZeneca, occurring in fewer than 20.3
per million individuals aged 18 to 49 years and 10.9 per
million in those aged 50 years and older, and should not dis-
courage the use of COVID-19 vaccination.31
Strengths and Limitations
Certain limitations must be acknowledged. The included studies
are not representative of the entire population due to TTS being a
deviation from the norm. This means that the data from the
included studies, while important, must be used and interpreted
Figure 3. ROC Curve for Vaccine Dosage (in blue), Gender (in green), and Age (in yellow) associated with Death (in purple) as the reference line.
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with caution. We could not include cohort studies because the
data could not be aligned to the post hoc analytical framework
of this study. Because certain countries were represented more
than others, we suspect that there has been an under-reporting
of fatality reports from low- and middle-income countries.
We present pertinent trends for the thromboses communities
worldwide, albeit with small sample size. The exploratory anal-
ysis presents a unique synthesis of all reported in-depth cases so
far in the literature. The pertinent data collated in this study will
help policymakers and clinicians to determine the persons at
risk, for a cautious approach. The global representation of
cases worldwide is worth noting.
Conclusion
In conclusion, adenoviral COVID-19 vaccines may trigger TTS
until 4 weeks after vaccination, especially among those with pro-
thrombotic risk factors. Clinicians ought to maintain a high degree
of suspicion when recently-vaccinated individuals present with
headaches or other symptoms suggestive of thrombosis.
Screening with blood tests should be considered. In the case of
thrombocytopenia that is not attributed to another cause, further
imaging and laboratory testing may be considered. HIT testing
is not highly sensitive for TTS, requiring the use of PF4 ELISA
HIT testing. It is also pertinent to avoid using heparin-based prod-
ucts among suspected or confirmed TTS patients. Importantly,
certain cases of mRNA COVID-19 vaccines have also been iden-
tified, complicating the sole implication of adenoviral COVID-19
vaccines for TTS. Public health efforts must continue focusing on
early recognition and treatment of TTS while also promoting vac-
cination to control the COVID-19 pandemic.
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